source
- Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 failEvommune’s MRGPRX2 antagonist has flunked another phase 2 trial, wiping out the biotech’s last hopes of developing the therapy for any itch-related conditions.
- AMA chief says AI will augment, not replace, physiciansJohn Whyte, the chief executive of the American Medical Association, wrote an opinion piece asserting that artificial intelligence should work alongside doctors rather than take their place. He po…